8-K: Centene Corporation Reports Strong Q2 2024 Results, Reaffirms Full-Year Guidance

Centene Corporation announced a 15% increase in adjusted diluted EPS to $2.42 for the second quarter of 2024, driven by Marketplace growth and cost management, while reaffirming its full-year adjusted EPS guidance.

Summary

• Centene Corporation reported its financial results for the second quarter of 2024, with total revenues reaching $39.8 billion.
• Premium and service revenues were $36.0 billion, a 3% increase compared to the same period last year.
• The company's adjusted diluted earnings per share (EPS) rose by 15% to $2.42, up from $2.10 in Q2 2023.
• Membership in the Marketplace segment saw a significant 34% increase year-over-year.
• Centene reaffirmed its 2024 adjusted diluted EPS guidance floor of greater than $6.80.
• The company is increasing its 2024 premium and service revenues guidance range by $5.0 billion to a range of $141.0 billion to $143.0 billion.
• The health benefits ratio (HBR) was 87.6%, an increase from 87.0% in the second quarter of 2023.
• Cash flow provided by operations was $2.2 billion for the quarter.
• Centene repurchased 10.7 million shares for $800 million during the quarter, with $4.4 billion remaining under the stock repurchase program.

Sentiment

Score: 7

Explanation: The sentiment is positive due to strong EPS growth, Marketplace performance, and reaffirmed guidance, but tempered by challenges in Medicaid and an increased HBR.

Positives

• Centene's adjusted diluted EPS increased by 15% year-over-year, indicating strong profitability.
• The Marketplace segment experienced substantial membership growth of 34%, demonstrating the success of their product offerings.
• The company's reaffirmation of its full-year adjusted EPS guidance provides confidence in its financial outlook.
• The increase in premium and service revenue guidance suggests positive momentum in the business.
• Centene's cash flow from operations was strong at $2.2 billion.
• The company's share repurchase program indicates a commitment to returning value to shareholders.

Negatives

• Medicaid membership decreased due to redeterminations, impacting overall membership numbers.
• The health benefits ratio (HBR) increased to 87.6%, driven by higher acuity in Medicaid and Medicare Star rating impacts.
• There was a decrease in premium and service revenues in the Medicaid segment by 8% year-over-year.
• The company experienced a decrease in other revenues by 22% year-over-year.

Risks

• Medicaid redeterminations are causing a decline in membership and impacting revenue.
• Higher acuity in Medicaid and Medicare Star rating impacts are increasing the health benefits ratio.
• The company faces risks related to managing health benefits and operating expenses.
• Competition in the healthcare industry could impact future growth and profitability.
• Changes in government healthcare programs and regulations could affect the company's business.

Future Outlook

Centene reaffirms its 2024 GAAP diluted EPS guidance floor of greater than $5.94 and its 2024 adjusted diluted EPS guidance floor of greater than $6.80. The company is increasing its 2024 premium and service revenues guidance range by $5.0 billion to a range of $141.0 billion to $143.0 billion. The 2024 HBR is expected to be at the high end of the previous guidance range, approximately 87.9%.

Management Comments

• While we have work to do in Medicaid as redeterminations wind down, the overall performance of the diversified portfolio enables us to remain on track for 2024 adjusted diluted EPS guidance, said Chief Executive Officer of Centene, Sarah M. London.
• At the same time, we continue to make important progress on operations and quality that positions us well to serve our members and deliver long-term profitable growth.

Industry Context

Centene's results reflect the ongoing challenges and opportunities in the managed healthcare industry, particularly with Medicaid redeterminations and the growth of the Marketplace segment. The company's performance is being impacted by the unwinding of the COVID-19 public health emergency and the associated redetermination of Medicaid eligibility, which is a common trend across the industry.

Comparison to Industry Standards

• Centene's 34% growth in Marketplace membership is a strong performance compared to many of its peers, indicating a successful strategy in this segment.
• The increase in HBR to 87.6% is a point of concern, as many managed care companies aim for lower ratios to improve profitability. This increase is driven by higher acuity in Medicaid and Medicare Star rating impacts, which are industry-wide challenges.
• The company's adjusted diluted EPS of $2.42 is a positive result, but it is important to compare this to the performance of other large managed care organizations such as UnitedHealth Group, Elevance Health, and Humana to fully assess its relative performance.
• Centene's reaffirmation of its full-year guidance is a positive sign, but the company will need to manage the impact of Medicaid redeterminations and other challenges to meet these targets.

Stakeholder Impact

• Shareholders will benefit from the increased EPS and share repurchase program.
• Members will be impacted by changes in Medicaid eligibility and the quality of services provided.
• Employees will be affected by the company's restructuring and cost management initiatives.
• Providers will be impacted by changes in reimbursement rates and contract terms.
• Government partners will be affected by the company's performance in government-sponsored healthcare programs.

Next Steps

• Centene will continue to manage the impact of Medicaid redeterminations.
• The company will focus on improving operations and quality to serve members and deliver long-term growth.
• Centene will work to close the sale of Collaborative Health Systems by the end of 2024.
• The company will implement the new three-year KanCare contract effective January 1, 2025.

Key Dates

Keywords

Centene, Healthcare, Financial Results, EPS, Medicaid, Medicare, Marketplace, Membership, Revenue, Health Benefits Ratio